Navigation Links
Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
Date:12/1/2011

n benefit in treating adult Dupuytren's contracture in patients with a palpable cord."

The phase IIa study is an open-label, controlled dose-ranging study designed to assess the safety and efficacy of XIAFLEX for the treatment of Frozen Shoulder syndrome in comparison to an exercise-only control group. The study will involve approximately 50 adult men and women at approximately nine sites throughout the U.S. Topline study results are expected in the first half of 2013.

To qualify for the Frozen Shoulder syndrome study, patients must have unilateral idiopathic adhesive capsulitis of the shoulder with restricted range of motion in the affected shoulder for at least three months, but not more than 12 months. Following screening and determination of study eligibility, subjects will be assigned to four groups that vary in dosing (injection volume and concentration) or a fifth group receiving shoulder exercises only. Patients may receive up to three ultrasound-guided injections of varying doses of XIAFLEX (ranging from 0.29 mg to 0.58 mg in varying concentrations) separated by a minimum of 21 days and all patients will be instructed to perform home shoulder exercises. The study's primary endpoint is the change (degrees) from baseline to the day 92 follow-up in forward flexion (active) in the affected shoulder. Safety assessments, including immunogenicity testing, will be made during all study visits. More information on the study, including study sites participating in this trial, can be found at clinicaltrials.gov.

About Frozen Shoulder Syndrome
Frozen Shoulder syndrome, also known as idiopathic adhesive capsulitis, is a common, prolonged, and painful disorder of diminished shoulder motion.(1)  The full duration of the frozen stage of disease can last from 1 to 3.5 years with a mean of 30 months.(4)  Increased capsular collagen thickening and subsequent capsular contraction in the glenohumeral joint is thought to cause restrictio
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
2. Auxilium Pharmaceuticals, Inc. Announces Publication of U.S. CPT® Codes and Related Reimbursement Rates for XIAFLEX®
3. Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011
4. Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytrens Contracture in E-poster at ASSH Meeting
5. Auxilium Pharmaceuticals Announces Positive Data from Commercial Patient Chart Review in E-posters at ASSH Meeting
6. Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study
7. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
8. Auxilium Pharmaceuticals Announces Investor Event to Occur at 2011 ASSH Meeting on September 9, 2011
9. Auxilium Pharmaceuticals to Present at the Stifel Nicolaus 2011 Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer
11. Auxilium Pharmaceuticals to Announce Second Quarter 2011 Results and Conduct Conference Call on Monday, August 1, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  HyGreen, Inc., a leader in hand ... with RCA Medical, a subsidiary of Ascendis Health Limited, ... Each year, hundreds of millions of patients around ... organisms are transmitted from patient to patient via the ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Oct. 3, 2011 Varian Medical Systems (NYSE: ... senior managers to support the company,s ongoing growth and ... Vice President for the company, has been named Chief ... development, production, promotion, and sale of all Varian products ...
...   PLC Medical Systems, Inc. (OTC: PLCSF) today announced ... , October 6, 2011TIME: , 11:00 AM ... "register/ watch event now" button.This will be a live, ... the company questions in real-time both in the presentation ...
Cached Medicine Technology:Varian Medical Systems Announces New Management Positions 2Varian Medical Systems Announces New Management Positions 3Varian Medical Systems Announces New Management Positions 4PLC Medical Systems to Present Webcast Live, at RetailInvestorConferences.com on October 6th 2
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... 22, 2015 As interest in the value ... gains momentum worldwide, Rev. Eric J. Hall , president ... (HCCN), will be the keynote speaker on January 27 ... public health system. , The conference, “Hope and Resilience: Innovative ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a list ... policy . , Some types of vehicles cannot be covered ... released blog post to see if their vehicle qualifies for auto ... some of the cars that cannot be covered by a plan. ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... Women and Men From 46 States and 7 ... ... participants in this,weekend,s fifth annual Avon Walk for Breast Cancer New York ... breast cancer. At,today,s Closing Ceremony at Hudson River Park,s Pier 84, Avon ...
... Prognosis improves in summer, fall, study finds , SUNDAY, Oct. ... the summer and fall have a better chance of survival ... study of Norwegian men suggests. , "Summer and autumn months ... Although the study does not prove vitamin D is the ...
... is linked to MRI exposure, scientists say , FRIDAY, ... a newly identified disease called nephrogenic systemic fibrosis (NSF) ... , The researchers also concluded that exposure to gadolinium, ... significant risk factor for developing NSF, a painful and ...
... groups,affiliated and aligned with Sutter Health have been ... highly respected health care leadership,group, the Integrated Healthcare ... annual Pay for Performance (P4P) report card. ... Regional Medical Group of the Sutter Regional Medical ...
... in Dallas-Ft. Worth, Hartford and Sacramento Markets, CHICAGO, Oct. 5 , Why: ... U.S. soldiers involved in the conflicts in ... Brain Injury (TBI), with 25 percent of blast ... blast survivors, leaving 5,500 service members with ...
... cancer, aside from non-melanoma,skin cancer, is the most common ... Disease Control and Prevention. It is the number one ... most in white, black,Asian/Pacific Islander and American Indian/Alaska Native ... just those who have been diagnosed,with it. (See ...
Cached Medicine News:Health News:Fifth Annual Avon Walk for Breast Cancer New York Raises $10.2 Million 2Health News:Fifth Annual Avon Walk for Breast Cancer New York Raises $10.2 Million 3Health News:Prostate Cancer Survival Varies by Season 2Health News:New Kidney Disease Can Be Fatal 2Health News:Sutter Health Medical Groups Among the Best for Health Care Quality 2Health News:Easter Seals Launches Program for Veterans Returning from Iraq and Afghanistan with Traumatic Brain Injuries 2Health News:Easter Seals Launches Program for Veterans Returning from Iraq and Afghanistan with Traumatic Brain Injuries 3
For the direct, colorimetric determination of calcium in human serum or urine. Linearity: 20 mg/dl....
Alanine Aminotransferase (ALT) reagent is used for the quantitative determination of alanine aminotransferase (Glutamate pyruvate transaminase, SGPT) in human serum....
For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution....
For the determination of urea nitrogen in human serum....
Medicine Products: